Relevant bibliographies by topics / Digoxin (digitalis)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Digoxin (digitalis)'

Author: Grafiati
Published: 4 June 2021
Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Digoxin (digitalis).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Digoxin (digitalis)"

1

Hollman, A. "Digoxin comes from Digitalis lanata." BMJ 312, no. 7035 (April 6, 1996): 912. http://dx.doi.org/10.1136/bmj.312.7035.912.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sharma, Anup, and Bulbul Purkait. "Quality Assessment of Serially Ultradiluted and Agitated Drug Digitalis purpurea by Emission Spectroscopy and Clinical Analysis of Its Effect on the Heart Rate of Indian Bufo melanostictus." Journal of Pharmaceutics 2013 (December 27, 2013): 1–6. http://dx.doi.org/10.1155/2013/571464.

Full text
Abstract:
The investigation of ultradiluted (homeopathic) drugs is extremely interesting and challenging, and from that point of view this study shows novelty. A study of in vivo changes in heart rate of the Indian Bufo melanostictus caused by commercially available serially ultra-diluted and agitated extract of Digitalis purpurea has been tried in order to understand their pharmacological role. RR interval (of ECG) was compared after intraperitoneal administration of serially diluted and agitated Digitalis purpurea extract, diluent rectified spirit, and Digoxin in anesthetized animals. The study revealed statistically significant changes in the heart rate after application of these drugs except in case of Digoxin and the 200th serial dilution of Digitalis purpurea. The duration of RR intervals after application of the drugs was corroborative of the effect of Digoxin and Digitalis purpurea extract up to 30th dilution. Emission spectra were obtained for the experimental ultra-diluted Digitalis purpurea extract and Digoxin to identify and characterize them. The observed RR pattern and emission spectra show an association. The quality assessment of the commercial ultra-diluted organic drugs obtained from natural products may be initiated by monitoring in vivo studies on animal models.
APA, Harvard, Vancouver, ISO, and other styles
3

Scherrmann, Jean Michel, Pierre Sandouk, and Xavier Guedeney. "Digitalis-like Factors and Digoxin Pharmacokinetics." Chest 89, no. 3 (March 1986): 468–69. http://dx.doi.org/10.1378/chest.89.3.468.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cole, Patricia L., and Thomas W. Smith. "Use of Digoxin-Specific Fab Fragments in the Treatment of Digitalis Intoxication." Drug Intelligence & Clinical Pharmacy 20, no. 4 (April 1986): 267–70. http://dx.doi.org/10.1177/106002808602000403.

Full text
Abstract:
The narrow margin between therapeutic and toxic effects of digitalis glycosides renders patients taking these drugs particularly susceptible to serious consequences of accidental or deliberate overdosage, including life-threatening arrhythmias. Until recently, the treatment of digitalis intoxication has been largely supportive. In the past decade, however, digoxin-specific antibodies have been developed and have proven to be effective in rapidly reversing the electrophysiologic and metabolic manifestations of digitalis intoxication, both in vitro and in vivo. Enzymatic cleavage of the intact antibody population into Fab fragments results in a more rapidly effective and less immunogenic antidote to digitalis excess. More recently, monoclonal antibodies with high affinity and specificity for digoxin have been produced by the technique of somatic cell fusion; application of this technique to the production of anti-digoxin antibodies has potential implications for the production of a highly purified homogeneous product, but this approach has not yet been tested clinically.
APA, Harvard, Vancouver, ISO, and other styles
5

Rabkin, Simon W., and Mark Redston. "The effect of inhibitors of endogenous opioid degradation, bacitracin, bestatin, captopril, and D-phenylalanine, on digoxin-induced arrhythmias in guinea pigs." Canadian Journal of Physiology and Pharmacology 67, no. 8 (August 1, 1989): 857–63. http://dx.doi.org/10.1139/y89-134.

Full text
Abstract:
The purpose of this study was to investigate the effect of inhibition of endogenous opioid degradation on digitalis-induced arrhythmias, utilizing the inhibitors bacitracin, bestatin, captopril, and D-phenylalanine. Guinea pigs, anesthetized with pentobarbital, 50 mg/kg i.p., and breathing spontaneously received intracerebroventricular (i.c.v.) injection of bacitracin (6.8 mg/kg), bestatin (1 mg/kg), captopril (2 mg/kg), D-phenylalanine (1.2 mg/kg) or the diluent, saline. Digitalis arrhythmias were induced by a 50 μg/kg i.v. bolus of digoxin followed by 500 μg∙kg−1∙h−1 i.v. Bacitracin and bestatin, but not captopril or D-phenylalanine, significantly (p < 0.05) altered the relationship between the digoxin dose and the first occurrence of arrhythmias, i.e., digoxin-induced ventricular arrhythmias became manifest at lower digoxin doses. The mean digoxin dose and ED50s, at which arrhythmias first occurred, were significantly (p < 0.05) reduced by bacitracin and bestatin. The findings were similar for fatal arrhythmias, although D-phenylalanine appeared to decrease the digoxin dose at the development of fatal arrhythmias. The opioid antagonist naloxone, in a 50 μg/kg bolus and 50 μg∙kg−1∙h−1 i.c.v., completely prevented these effects of bacitracin and reduced the effect of bestatin. The relationship to arrhythmias could not be ascribed to an effect on blood pressure, as the blood pressure response to digoxin was the same in bestatin, D-phenylalanine, and control groups. To examine whether systemic administration of an inhibitor of opioid degradation had similar effects, a second protocol was selected with systemic administration of bacitracin because it altered the dose effect relationship after i.c.v. administration and systemic concentrations could be readily attained. Bacitracin, in a 13.5 mg/kg i.v. bolus and 135 mg∙kg−1∙h−1 i.v., was followed by 100 μg/kg digoxin i.v. every 15 min. Bacitracin significantly (p < 0.05) reduced the digoxin dose at the development of arrhythmias. This was reversed by naloxone, given as 2 mg/kg i.v. plus 10 mg∙kg−1∙h−1. Thus, these data indicate that inhibitors of degradation of some opioid potentiate digitalis arrhythmias in a manner that is inhibited by naloxone, and provide evidence that implicates a role for endogenous opioids in digitalis arrhythmias.Key words: digitalis arrhythmias, aminopeptidase inhibitors.
APA, Harvard, Vancouver, ISO, and other styles
6

Rodríguez-Calvo, María S., Rosa Rico, Manuel López-Rivadulla, José M. Suárez-Peñaranda, José I. Muñoz, and Luis Concheiro. "2. Report of a Suicidal Digoxin Intoxication: A Case Report." Medicine, Science and the Law 42, no. 3 (July 2002): 265–68. http://dx.doi.org/10.1177/002580240204200313.

Full text
Abstract:
Digoxin is a cardiotonic glycoside that is primarily used in the treatment of heart failure, atrial fibrillation or flutter, and paroxysmal atrial tachycardia. Intoxication due to digitalis excess is a common problem in clinical practice because it is therapeutically effective within a narrow dose range. However, massive intoxication with digitalis glycosides following a suicidal attempt is a rare event. In this report we describe an overdose fatality involving digoxin in a suicidal 82-year-old man, in whom measurement of serum digoxin concentration is available. A toxicological study of our patient, approximately two and a half hours after ingestion of the drug, revealed digoxin concentrations within 12.2–13.2 ng/ml in the blood, while the mean therapeutic serum concentration ranged from 0.5 to 2 ng/ml.
APA, Harvard, Vancouver, ISO, and other styles
7

Sabatini, Diletta, Giovanni Truscelli, Antonio Ciccaglioni, Carlo Gaudio, and Maria Caterina Grassi. "Bidirectional Tachycardia after an Acute Intravenous Administration of Digitalis for a Suicidal Gesture." Case Reports in Psychiatry 2014 (2014): 1–3. http://dx.doi.org/10.1155/2014/109167.

Full text
Abstract:
Acute digoxin intoxication is a life-threating condition associated with severe cardiotoxicity. Female gender, age, low lean body mass, hypertension, and renal insufficiency may worsen the prognosis. Arrhythmias caused by digitalis glycosides are characterized by an increased automaticity coupled with concomitant conduction delay. Bidirectional tachycardia is pathognomonic of digoxin intoxication, but it is rarely observed. An 83-year-old woman was admitted to the Emergency Department after self-administration of 5 mg of digoxin i.v. for suicidal purpose. Her digoxin serum concentration was 17.4 ng/mL. The patient developed a bidirectional tachycardia and the Poison Control Center of the hospital provided digoxin immune fab. Bidirectional tachycardia quickly reversed and the patient remained stable throughout the hospital stay. This case shows that a multiple disciplinary approach, involving cardiologists and toxicologists, is essential for the management of digoxin intoxication. The optimal treatment of this rare event depends on the clinical conditions and on the serum drug concentration of the patient. Digoxin immune fab represents a safe, effective, and specific method for rapidly reversing digitalis cardiotoxicity and should be started as soon as the diagnosis is defined.
APA, Harvard, Vancouver, ISO, and other styles
8

Longerich, L., S. Vasdev, E. Johnson, and M. H. Gault. "Disposable-column radioimmunoassay for serum digoxin with less interference from metabolites and endogenous digitalis-like factors." Clinical Chemistry 34, no. 11 (November 1, 1988): 2211–16. http://dx.doi.org/10.1093/clinchem/34.11.2211.

Full text
Abstract:
Abstract A preparative extraction step using disposable C18 low-pressure chromatography columns greatly improved the specificity of a commercially prepared digoxin radioimmunoassay (RIA). Elution solvents were isopropanol/water (15/85 by vol), which extracted most immunoreactive digitalis-like factors and metabolites, and methanol, which extracted digoxin for RIA. Many different digoxin RIA kits could be used. The coefficients of variation for replicates and duplicates were 4.6% and 5.2%. Analytical recoveries of digoxin standards in serum of 1.0, 0.5, and 0.1 microgram/L were 96%, 95%, and 88%, respectively. Serum digoxin was assayed by this method in 200 patients, 47 of whom were studied by HPLC-RIA. Values correlated better with "true digoxin" by HPLC-RIA (r = 0.93) than did values found by direct assay (r = 0.63). The mean for the isopropanol fraction as a percentage of the mean direct RIA value was higher for the 21 dialysis-dependent patients than was that found for the 179 nondialysis patients (P less than 0.004). The method is suggested as being most useful when metabolites or digitalis-like factors are known to be often high and values for digoxin are disproportionate to the dose.
APA, Harvard, Vancouver, ISO, and other styles
9

Malini, Pier Luigi, Enrico Strocchi, Giorgio Feliciangeli, Andrea Buscaroli, Vittorio Bonomini, and Ettore Ambrosioni. "DIGITALIS RECEPTORS AND DIGOXIN SENSITIVITY IN RENAL FAILURE." Clinical and Experimental Pharmacology and Physiology 12, no. 2 (April 1985): 115–20. http://dx.doi.org/10.1111/j.1440-1681.1985.tb02313.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lengel, Matthew J., Kun Xiang, Vincent F. Mauro, Blair P. Grubb, and Christopher J. Cooper. "Acute Digitalis Delirium Associated with Intravenous Digoxin Administration." Arrhythmia grand rounds 1, no. 1 (April 27, 2015): 3–6. http://dx.doi.org/10.12945/j.agr.2015.0002-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Digoxin (digitalis)"

1

Ma, Jie. "Human Endogenous Sodium Pump Inhibitors Measurement, Source, Synthesis and Regulation." BYU ScholarsArchive, 2011. https://scholarsarchive.byu.edu/etd/2953.

Full text
Abstract:
The sodium pump (SP or Na+,K+-ATPase) is a membrane embedded protein complex that pumps 3 sodium ions out and 2 potassium ions into the cell per cycle and in so doing creates a cell membrane electrochemical potential. The membrane potential is critical for any functional cell. In the vasculature, reduction in the voltage potential causes vascular smooth muscle contraction and a narrowing of blood vessels (vasoconstriction) which can lead to increased blood pressure (hypertension). Substantial research over the past several decades has provided a vast amount of research on SP inhibitors, sometimes called endogenous digitalis-like factors (EDLF). Increased levels of these factors have been implicated in many hypertensive disorders including preeclampsia (PE), a life-threatening complication of pregnancy. It has been demonstrated that EDLF might be a causative factor in the pathophysiology of hypertension in PE. In order to elucidate EDLF production and regulation in PE, We developed a radioimmunoassay (RIA) measuring EDLF that could be applied to serum from pregnant women, placental homogenate and placental tissue culture. This assay employs Digibind, a commercially available Fab fragment derived from polyclonal antidigoxin antibodies that cross reacts with EDLF, as the primary antibody. Using Digibind RIA, we demonstrated that placenta is a source of EDLF production and regulation. Moreover, the identification of an inhibitor, ketoconazole and a substrate, 17-hydroxyprogesterone of the synthetic pathway of EDLF in placenta proved that this pathway shares steps with the steroid synthetic pathway. Some potential regulatory agents which have elevated levels in PE or be associated in PE and thus are thought to mediate PE, such as hydrogen peroxide, tumor necrosis factor-α (TNF-α) and hypoxia have also been demonstrated to be stimuli of EDLF production in placenta. These findings are helpful to the further study on EDLF synthesis and regulation in placenta. Once we elucidate the mechanisms, it could be easier to provide deeper insights into the pathogenesis of PE and subsequently develop earlier diagnosis and effective prevention of or therapeutic approaches to PE.
APA, Harvard, Vancouver, ISO, and other styles
2

Hopoate-Sitake, Moana Lee. "A Novel Use of Digoxin Immune Fab Fragment in Identification and Isolation of an Endogenous Digitalis-like Factor Found in Preeclampsia." BYU ScholarsArchive, 2011. https://scholarsarchive.byu.edu/etd/2599.

Full text
Abstract:
The mechanisms mediating the hypertension of preeclampsia (PE) are unclear. Endogenous digitalis-like factors (EDLFs) are specific sodium pump (SP) inhibitors implicated in essential and experimental hypertension, but they have not been fully explored in the setting of PE. This study uses a digoxin antibody Fab fragment to address the question of whether such factors are present and increased in PE, to investigate a possible treatment of PE, and to isolate and characterize all EDLFs present in PE. Sera and placenta from women with PE did show a significant increase in SP inhibition in comparison to women with normal pregnancy and Digibind® was found to bind EDLFs and essentially block or reverse SP inhibition. Sera were collected in a Phase II, double-blind, placebo controlled clinical study in which women with severe preeclampsia were dosed with Digibind®, as a therapeutic, and the SP activity measured. Sera and placenta from women with PE was also investigated for their inhibitory effects on the SP. Known candidates for EDLFs were investigated for their SP inhibitory effects, as well as how digitalis antibody immune Fab fragments, Digibind® and DigiFab™, bound them and affected the SP activity. Digibind® is also a sufficient affinity material used to isolate and purify PE EDLFs. Additionally, the placentas of preeclamptic women have high levels of similar EDLFs. These studies provide evidence for the existence of EDLFs that circulate in women with PE, and Digibind® is an effective and novel tool to bind, isolate and purify EDLFs in PE.
APA, Harvard, Vancouver, ISO, and other styles
3

Inocencio, André Luís. "Purificação e caracterização do fragmento Fab anti-digoxina obtido pela técnica de phage display." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-25082016-085639/.

Full text
Abstract:
A digoxina é um dos medicamentos indicados para o tratamento de falência cardíaca. Possui janela terapêutica estreita, sendo responsável por casos de intoxicação. O único antídoto disponível para a desintoxicação é o anticorpo policlonal DigiFab®, no formato Fab. O seu uso é eficaz, porém de custo elevado. Clones bacterianos produtores de fragmento Fab monoclonal anti-digoxina foram obtidos previamente pelo nosso grupo, pela técnica de phage display. Neste trabalho as variantes Fab dos 4 clones foram expressas em E.coli para estabelecer o método para a purificação. Com a obtenção dos fragmentos Fab purificados, foi caracterizada a sua afinidade ao antígeno e especificidade, em ensaios de inibição por digoxina, digitoxina, digoxigenina e ouabaina. Os parâmetros cinéticos da ligação dos fragmentos Fab dos 4 clones e do DigiFab® foram avaliados por SPR. Nas condições experimentais, não foram verificadas diferenças significativas entre os produtos dos 4 clones e o comercial, demonstrando o potencial dos fragmentos Fab monoclonais obtidos como antídoto à digoxina.
Digoxin is a medication indicated for heart failure treatment. Its therapeutic window is narrow, being responsible for intoxication cases. The only antidote available for the detoxification is a polyclonal antibody - DigiFab® in Fab format. Its use is effective, but costly. Bacterial clones producing anti-digoxin monoclonal Fab fragments were previously obtained by our group using phage display technology. In this work the Fab variants of the 4 clones were expressed in E.coli to establish the purification method. The purified fragments were characterized regarding the affinity to the antigen and the specificity through inhibition assays with digoxin, digitoxin, digoxigenin and ouabain. The binding kinetic parameters of Fab fragments of the 4 clones and the commercial product to Dig-BSA conjugate were assessed by SPR. Under the experimental conditions no significant differences were observed among the 4 clones and the commercial product, demonstrating the potential of monoclonal Fab fragments as an antidote to digoxin.
APA, Harvard, Vancouver, ISO, and other styles
4

CLADET, PHILIPPE. "Digoxine - digitaline : le choix du traitement face au risque de surdosage chez la personne agee : a propos de 46 observations." Lille 2, 1990. http://www.theses.fr/1990LIL2M029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brugidou, Christophe. "Développement de Digitalis lanata (Ehrh.) et sélection pour la production d'un hétéroside cardiotonique, la digoxine." Grenoble 2 : ANRT, 1987. http://catalogue.bnf.fr/ark:/12148/cb376034842.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brugidou, Christophe. "Developpement de digitalis lanata (ehrh. ) et selection pour la production d'un heteroside cardiotonique : la digoxine." Paris 6, 1987. http://www.theses.fr/1987PA066288.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Reibel, Monique. "Le dosage des digitaliques chez l'hemodialyse : pharmacocinetique de la digitoxine, presence d'une activite digitalis-like endogene." Strasbourg 1, 1988. http://www.theses.fr/1988STR1M058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mesquita, Regina Clelia da Costa. "Separação de uma mistura de compostos digitalicos em escala semi-preparativa atraves de cromatografia liquida por deslocamento." [s.n.], 1994. http://repositorio.unicamp.br/jspui/handle/REPOSIP/249755.

Full text
Abstract:
Orientador : Carol H. Collins
Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Quimica
Made available in DSpace on 2018-07-19T12:02:21Z (GMT). No. of bitstreams: 1 Mesquita_ReginaCleliadaCosta_M.pdf: 7376205 bytes, checksum: 64733609cb260a0a2d7b48e3dbc2b0d2 (MD5) Previous issue date: 1994
Mestrado
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Digoxin (digitalis)"

1

Lapostolle, Frédéric, and Stephen W. Borron. Management of digoxin poisoning. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0323.

Full text
Abstract:
Despite a gradual decline in the clinical use of digitalis glycosides, digitalis toxicity continues to be responsible for substantial morbidity and mortality, particularly among the elderly. Digitalis poisoning may occur acutely, after intentional overdose, but is more often seen as the result of chronic intoxication among patients receiving digitalis therapy. Clinical findings in chronic digitalis poisoning are often subtle. The astute clinician will enquire about digitalis use in older patients with vague complaints and will not be dissuaded from considering digitalis toxicity in the face of a ‘therapeutic’ digitalis blood concentration. Two digitalis preparations continue to be used with frequency, depending on geography. Digoxin is the digitalis glycoside of choice in the USA, while digitoxin prevails in some parts of Europe. While the methods and half-lives of elimination differ markedly for these two substances, the approach to poisoning by either is similar. Advanced age, underlying cardiovascular disease, and severe hyperkalaemia represent poor prognostic factors in digitalis poisoning. Early administration of digitalis Fab fragments should be undertaken when life-threatening symptoms are present. Prophylactic therapy with reduced doses of Fab fragments should be strongly considered for less serious toxicity.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Digoxin (digitalis)"

1

Schmidt, Thomas A., and Keld Kjeldsen. "Regulation of Digitalis Glycoside Receptors in Digoxin Treatment." In Cardiac Remodeling and Failure, 501–10. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4419-9262-8_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wenger, T., V. P. Butler, E. Haber, and T. W. Smith. "Digoxin-specific antibody treatment of digitalis toxicity: Update." In Cardiac Glycosides 1785–1985, 377–82. Heidelberg: Steinkopff, 1986. http://dx.doi.org/10.1007/978-3-662-11292-2_50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Smith, Thomas W. "Digoxin-Specific Fab Fragments in the Treatment of Digitalis Intoxication." In Pediatric Cardiology, 1255–58. New York, NY: Springer New York, 1986. http://dx.doi.org/10.1007/978-1-4613-8598-1_333.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schmidt, T. A., H. Bundgaard, H. L. Olesen, N. H. Secher, and K. Kjeldsen. "Digoxin Treatment and Congestive Heart Failure in Light of Human Cardiac and Skeletal Muscle Digitalis Glycoside Receptor Studies." In The Sodium Pump, 832–35. Heidelberg: Steinkopff, 1994. http://dx.doi.org/10.1007/978-3-642-72511-1_152.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Asopa, Amit, and Swaminathan Karthik. "Digitalis (Digoxin)." In Essence of Anesthesia Practice, 599. Elsevier, 2011. http://dx.doi.org/10.1016/b978-1-4377-1720-4.00521-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cleland, John G. F., and Yura Mareev. "HFrEF pharmacological treatment: digitalis glycosides." In ESC CardioMed, 1867–72. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0428.

Full text
Abstract:
About 25 years ago, a series of trials suggested that withdrawal of digoxin from patients with heart failure who were stable, had mild symptoms, a reduced left ventricular ejection fraction, and in sinus rhythm could lead to worsening symptoms. Withdrawal of digoxin was also associated with a decline in renal function and weight gain, suggesting important renal effects, as well as a decline in left ventricular ejection fraction and exercise capacity. However, stopping a medication in a patient who has responded to it may carry bias; the effect of initiating digoxin in a digoxin-naïve patient is unknown. A large outcome study showed no effect on mortality. Since then, however, the evidence both for and against digoxin has been superseded by important innovations in therapy, such as beta blockers and mineralocorticoid antagonists. For patients in atrial fibrillation, evidence of a clinical benefit other than ventricular rate control, itself a controversial issue, is lacking. Current European Society of Cardiology Guidelines on heart failure suggest a limited role for digoxin for the management of symptoms of heart failure when other treatments have failed. New studies investigating the role of digitalis glycosides in patients with heart failure receiving contemporary background therapy are ongoing.
APA, Harvard, Vancouver, ISO, and other styles
7

Caquet, René. "Digitaline-digoxine Dosage des digitaliques." In Guide infirmier des examens de laboratoire, 107. Elsevier, 2008. http://dx.doi.org/10.1016/b978-2-294-70220-4.50053-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Digoxin (digitalis)"

1

Martínez Simón, JJ, A. Martín Suárez, AM Gómez Pedrero, and M. Pérez Encinas. "5PSQ-023 Adequate digoxin dosage in patients with digitalis toxicity." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.456.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Digoxin (digitalis)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography